UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer

Grant

Date/time Interval

  • August 29, 2013 - August 28, 2019
  • Awarded By

    Total Award Amount

  • 46700.00
  • Direct Costs

  • 37063.00
  • Sponsor Award Id

  • Contributor

  • Nabell M.D., Lisle   Investigator  
  • Rocque M.D., Gabrielle   Investigator